Zhejiang Gongdong Medical Technology's declining ROCE and sales trends are worrisome, particularly as the company is using more capital than five years ago. Despite this, the stock has given a 4.7% return to shareholders in the last three years. If these trends continue, better investment opportunities may exist elsewhere.